Zealand Rushes Out Good Safety News On Phase III Dasiglucagon Rescue Pen
Early results confirm dasiglucagon's safety profile with no treatment-induced or treatment-boosted anti-drug antibodies.
You may also be interested in...
Zealand Pharma stresses fast onset of dasiglucagon, which it plans to file on its own but develop commercially through partnership.
A number of pivotal studies are expected to report top-line data in the third quarter. Here, with the help of Informa Pharma's Biomedtracker, we take a look at eight of those likely to be major catalysts for their sponsors.
Evotec’s multimodality approach to drug discovery landed the biotech two new discovery collaborations this week, underscoring its emphasis on patient-driven data.